Stay updated on SubQ Efgartigimod in CIDP Clinical Trial

Sign up to get notified when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Efgartigimod in CIDP Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page now presents the ClinicalTrials.gov record for the completed Phase 2 ADHERE study of subcutaneous efgartigimod for adults with CIDP, including study design, outcome measures, eligibility criteria, and study documents.
    Difference
    100%
    Check dated 2026-11-13T02:24:15.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The displayed ClinicalTrials.gov revision changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error rather than study details.
    Difference
    0.2%
    Check dated 2026-10-30T02:52:58.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    A sitewide NIH notice was added above the ClinicalTrials.gov navigation, announcing a terminology transition from “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs. The study page continues to display a 403 error.
    Difference
    1%
    Check dated 2026-10-23T02:25:47.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2 while the page continued to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-16T02:54:34.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-09T03:06:31.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error instead of the study details, indicating access to the record is blocked or unavailable.
    Difference
    16%
    Check dated 2026-09-25T02:29:36.000Z thumbnail image

Stay in the know with updates to SubQ Efgartigimod in CIDP Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.